Penwest drops "not approvable" beta blocker
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Penwest halts efforts to develop beta blocker PW2101 for hypertension and angina following receipt of a "not approvable" letter from FDA, announced June 29. The firm filed the NDA Aug. 30 under the 505(b)(2) approval pathway, setting a user fee deadline of June 30. FDA issued the letter due to "the degree of kinetic variability of PW2101 observed among individuals and because beta blockade as a surrogate for efficacy was not demonstrated across the entire inter-dosing interval on an individual subject basis," Penwest said. PW2101 uses Penwest's TIMERx oral controlled-release delivery system...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.